AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Target
Upside 194%
Price (€) 3.34
Market Cap (€M) 121
Perf. 1W: 4.05%
Perf. 1M: -18.1%
Perf. 3M: 3.68%
Perf Ytd: 17.9%
10 day relative perf. to stoxx600: -6.24%
20 day relative perf. to stoxx600: -17.9%
Latest21/12/2018

Success of the capital increase

Fact

Crossject has announced that the c.€4m capital increase had been subscribed with, among others, c. 1,656k shares by Gemmes Venture (the group’s historic shareholder, which now controls 30.6% of the share capital) out of a total of c.3.4m new shares. The new number of shares stands at 13.6m and new shares will be listed as from 28 December.


Impact

The capital increase was already included in our numbers. We will only adjust them to account for the conversion of warrants since September that led to a high number of shares pre capital increase.


Updates

10 Sep 19 Earnings/sales releases
H1 19: no surprise

10 Jul 19 Financing issue
Warrants to existing shareholders

19 Jun 19 Latest
A commercial success

18 Apr 19 EPS change
The 2018 bonds fully converted

18 Mar 19 EPS change
No major change post FY18 results

15 Mar 19 Earnings/sales releases
Slowly but surely

04 Feb 19 Financing issue
Some extra non-dilutive financing

24 Dec 18 EPS change
Adjustment in the number of shares

.